Drug Trial Radar · NCT05254327
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
118
Planned (sponsor's estimate)
Start
Aug 15, 2022
Primary completion
May 2030
Study completion Jun 2034
Sponsor
- Lead sponsor
- University of NebraskaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BioMimetix JV, LLC
- First posted
- Feb 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.
Conditions
- Rectal Cancer
Interventions
BMX-001Drug
Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of BMX-001 as measured by Grade 3 and above associated with gastrointestinal ToxicitiesTime frame: Three weeks (During and 2 weeks after RT)
- Efficacy of BMX-001 as measured by Grade 3 and above associated with genitourinary ToxicitiesTime frame: Three weeks (During and 2 weeks after RT)
- Efficacy of BMX-001 as measured by Grade 3 and above associated with skin ToxicitiesTime frame: Three weeks (During and 2 weeks after RT)
- Efficacy of BMX-001 as measured by Grade 3 and above associated with hematologic ToxicitiesTime frame: Three weeks (During and 2 weeks after RT)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Markey Cancer Center
Lexington, Kentucky · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.